These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8297727)

  • 1. L1210 cells selected for resistance to methoxymorpholinyl doxorubicin appear specifically resistant to this class of morpholinyl derivatives.
    Geroni C; Pesenti E; Broggini M; Belvedere G; Tagliabue G; D'Incalci M; Pennella G; Grandi M
    Br J Cancer; 1994 Feb; 69(2):315-9. PubMed ID: 8297727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular glutathione heterogeneity in L1210 murine leukemia sublines made resistant to DNA-interacting anti-neoplastic agents.
    Tagliabue G; Pifferi A; Balconi G; Mascellani E; Geroni C; D'Incalci M; Ubezio P
    Int J Cancer; 1993 May; 54(3):435-42. PubMed ID: 8509218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of L1210 leukemia cells resistant to the distamycin-A derivative (FCE 24517): characterization and cross-resistance studies.
    Geroni C; Pesenti E; Tagliabue G; Ballinari D; Mongelli N; Broggini M; Erba E; D'Incalci M; Spreafico F; Grandi M
    Int J Cancer; 1993 Jan; 53(2):308-14. PubMed ID: 8425770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.
    Ganapathi R; Grabowski D; Sweatman TW; Seshadri R; Israel M
    Br J Cancer; 1989 Dec; 60(6):819-26. PubMed ID: 2605093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells.
    Ripamonti M; Pezzoni G; Pesenti E; Pastori A; Farao M; Bargiotti A; Suarato A; Spreafico F; Grandi M
    Br J Cancer; 1992 May; 65(5):703-7. PubMed ID: 1586598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effect of the calmodulin inhibitor trifluoperazine in modulating cellular accumulation, retention and cytotoxicity of doxorubicin in progressively doxorubicin-resistant L1210 mouse leukemia cells. Lack of correlation between cellular doxorubicin levels and expression of resistance.
    Ganapathi R; Grabowski D
    Biochem Pharmacol; 1988 Jan; 37(2):185-93. PubMed ID: 3342075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms for high methoxymorpholino doxorubicin cytotoxicity in doxorubicin-resistant tumor cell lines.
    Bakker M; Renes J; Groenhuijzen A; Visser P; Timmer-Bosscha H; Müller M; Groen HJ; Smit EF; de Vries EG
    Int J Cancer; 1997 Nov; 73(3):362-6. PubMed ID: 9359483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
    Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
    Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic conversion of methoxymorpholinyl doxorubicin: from a DNA strand breaker to a DNA cross-linker.
    Lau DH; Duran GE; Lewis AD; Sikic BI
    Br J Cancer; 1994 Jul; 70(1):79-84. PubMed ID: 8018545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calmodulin inhibitor trifluoperazine in combination with doxorubicin induces the selection of tumour cells with the multidrug resistant phenotype.
    Kamath N; Grabowski D; Ford J; Ganapathi R
    Br J Cancer; 1993 Jun; 67(6):1203-8. PubMed ID: 8099806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of DNA cross-linking to cis-diamminedichloroplatinum(II)-induced cytotoxicity in sensitive and resistant lines of murine leukemia L1210 cells.
    Strandberg MC; Bresnick E; Eastman A
    Chem Biol Interact; 1982 Mar; 39(2):169-80. PubMed ID: 7199396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells.
    Hromas RA; Andrews PA; Murphy MP; Burns CP
    Cancer Lett; 1987 Jan; 34(1):9-13. PubMed ID: 3802072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trifluoperazine modulation of resistance to the topoisomerase II inhibitor etoposide in doxorubicin resistant L1210 murine leukemia cells.
    Kamath N; Grabowski D; Ford J; Drake F; Kerrigan D; Pommier Y; Ganapathi R
    Cancer Commun; 1991 Feb; 3(2):37-44. PubMed ID: 1995027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular pharmacokinetics of aclacinomycin A in cultured L1210 cells. Comparison with daunorubicin and doxorubicin.
    Zenebergh A; Baurain R; Trouet A
    Cancer Chemother Pharmacol; 1982; 8(2):243-9. PubMed ID: 6955072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
    Lau DH; Lewis AD; Ehsan MN; Sikic BI
    Cancer Res; 1991 Oct; 51(19):5181-7. PubMed ID: 1717140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
    Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
    Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time course of MDR gene amplification during in vivo selection for doxorubicin-resistance and during reversal in murine leukemia L 1210.
    Volm M; Mattern J; Pommerenke EW
    Anticancer Res; 1991; 11(2):579-85. PubMed ID: 1676579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
    Rappa G; Lorico A; Sartorelli AC
    Cancer Res; 1993 Nov; 53(22):5487-93. PubMed ID: 8106148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L1210 cells cultivated under the selection pressure of doxorubicin or vincristine express common mechanisms of multidrug resistance based on the overexpression of P-glycoprotein.
    Bohácová V; Sulová Z; Dovinová I; Poláková E; Barancík M; Uhrík B; Orlický J; Breier A
    Toxicol In Vitro; 2006 Dec; 20(8):1560-8. PubMed ID: 16962737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversing multidrug resistance in L1210 tumor cells by hycanthone or chlorophenoxamine in vitro and in vivo.
    Efferth T; Klett T; Mattern J; Osswald H; Pommerenke EW; Stöhr M; Volm M
    Anticancer Res; 1991; 11(3):1275-9. PubMed ID: 1888160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.